According to the first clinical data published since the experiment launched in March 2021, 91% of patients report being satisfied with the medication.
Despite this positive response, the results are expected to have little or no impact on France’s more comprehensive medical cannabis trial, which was recently extended for another year in order for more data to be gathered.
Benjamin-Alexandre Jeanroy of Paris-based cannabis consultancy Augur Associates echoed this, adding that it would have been ‘surprising’ if these results weren’t positive, as these indications were explicitly selected for the trial because medical cannabis had already been ‘assessed as efficient’.